Cargando…

Reasons for Receiving or Not Receiving Bivalent COVID-19 Booster Vaccinations Among Adults — United States, November 1–December 10, 2022

Detalles Bibliográficos
Autores principales:	Sinclair, Alyssa H., Taylor, Morgan K., Weitz, Joshua S., Beckett, Stephen J., Samanez-Larkin, Gregory R.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Centers for Disease Control and Prevention 2023
Materias:	Full Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9869746/ https://www.ncbi.nlm.nih.gov/pubmed/36656784 http://dx.doi.org/10.15585/mmwr.mm7203a5

Ejemplares similares

COVID-19 Bivalent Booster Vaccination Coverage and Intent to Receive Booster Vaccination Among Adolescents and Adults — United States, November–December 2022
por: Lu, Peng-jun, et al.
Publicado: (2023)

Bivalent second booster dose of the COVID-19 vaccine: Eligible populations’ reasons for receiving in Italy
por: Della Polla, Giorgia, et al.
Publicado: (2023)

COVID-19 Incidence and Mortality Among Unvaccinated and Vaccinated Persons Aged ≥12 Years by Receipt of Bivalent Booster Doses and Time Since Vaccination — 24 U.S. Jurisdictions, October 3, 2021–December 24, 2022
por: Johnson, Amelia G., et al.
Publicado: (2023)

Interim Recommendations from the Advisory Committee on Immunization Practices for the Use of Bivalent Booster Doses of COVID-19 Vaccines — United States, October 2022
por: Rosenblum, Hannah G., et al.
Publicado: (2022)

Effectiveness of bivalent mRNA booster vaccination against SARS-CoV-2 Omicron infection, the Netherlands, September to December 2022
por: Huiberts, Anne J, et al.
Publicado: (2023)

Communicating COVID-19 exposure risk with an interactive website counteracts risk misestimation
por: Sinclair, Alyssa H., et al.
Publicado: (2023)

Effectiveness of Bivalent mRNA Vaccines in Preventing Symptomatic SARS-CoV-2 Infection — Increasing Community Access to Testing Program, United States, September–November 2022
por: Link-Gelles, Ruth, et al.
Publicado: (2022)

Effectiveness of bivalent COVID-19 boosters against COVID-19 mortality in people aged 65 years and older, Australia, November 2022 to May 2023
por: Liu, Bette, et al.
Publicado: (2023)

Safety Monitoring of Bivalent COVID-19 mRNA Vaccine Booster Doses Among Persons Aged ≥12 Years — United States, August 31–October 23, 2022
por: Hause, Anne M., et al.
Publicado: (2022)

CERN Courier Volume 62, Number 6, November/December 2022
por: CERN Communication Team
Publicado: (2022)

Early Estimates of Bivalent mRNA Vaccine Effectiveness in Preventing COVID-19–Associated Emergency Department or Urgent Care Encounters and Hospitalizations Among Immunocompetent Adults — VISION Network, Nine States, September–November 2022
por: Tenforde, Mark W., et al.
Publicado: (2022)

Early Estimates of Bivalent mRNA Vaccine Effectiveness in Preventing COVID-19–Associated Emergency Department or Urgent Care Encounters and Hospitalizations Among Immunocompetent Adults — VISION Network, Nine States, September–November 2022
por: Tenforde, Mark W., et al.
Publicado: (2023)

Safety Monitoring of COVID-19 Vaccine Booster Doses Among Persons Aged 12–17 Years — United States, December 9, 2021–February 20, 2022
por: Hause, Anne M., et al.
Publicado: (2022)

Early Estimates of Bivalent mRNA Booster Dose Vaccine Effectiveness in Preventing Symptomatic SARS-CoV-2 Infection Attributable to Omicron BA.5– and XBB/XBB.1.5–Related Sublineages Among Immunocompetent Adults — Increasing Community Access to Testing Program, United States, December 2022–January 2023
por: Link-Gelles, Ruth, et al.
Publicado: (2023)

Early Estimates of Bivalent mRNA Vaccine Effectiveness in Preventing COVID-19–Associated Hospitalization Among Immunocompetent Adults Aged ≥65 Years — IVY Network, 18 States, September 8–November 30, 2022
por: Surie, Diya, et al.
Publicado: (2022)

The “Great Debate” at Immunotherapy Bridge 2022, Naples, November 30th–December 1st, 2022
por: Ascierto, Paolo A., et al.
Publicado: (2023)

Reduced Odds of Mpox-Associated Hospitalization Among Persons Who Received JYNNEOS Vaccine — California, May 2022–May 2023
por: Schildhauer, Samuel, et al.
Publicado: (2023)

November-December 2007
Publicado: (2007)

November-December 2006
Publicado: (2006)

November-December 2004
Publicado: (2004)

November-December 2005
Publicado: (2005)

Willingness to Receive a COVID-19 Vaccination Among Incarcerated or Detained Persons in Correctional and Detention Facilities — Four States, September–December 2020
por: Stern, Marc F., et al.
Publicado: (2021)

Durability of Bivalent Boosters against Omicron Subvariants
por: Lin, Dan-Yu, et al.
Publicado: (2023)

Update on Vaccine-Derived Poliovirus Outbreaks — Worldwide, January 2021–December 2022
por: Bigouette, John Paul, et al.
Publicado: (2023)

Disparities in COVID-19 Vaccine Booster Uptake in the USA: December 2021–February 2022
por: Gaffney, Adam, et al.
Publicado: (2022)

Effectiveness of Bivalent Boosters against Severe Omicron Infection
por: Lin, Dan-Yu, et al.
Publicado: (2023)

Investigation of SARS-CoV-2 Transmission Associated With a Large Indoor Convention — New York City, November–December 2021
por: Sami, Samira, et al.
Publicado: (2022)

Investigating the Reasons for Receiving the Second Booster Dose of the COVID-19 Vaccine in Adults and in People with Chronic Medical Conditions in Southern Italy
por: Miraglia del Giudice, Grazia, et al.
Publicado: (2023)

Mpox Cases Among Cisgender Women and Pregnant Persons — United States, May 11–November 7, 2022
por: Oakley, Lisa P., et al.
Publicado: (2023)

Mask Use and Ventilation Improvements to Reduce COVID-19 Incidence in Elementary Schools — Georgia, November 16–December 11, 2020
por: Gettings, Jenna, et al.
Publicado: (2021)

COVID-19 Vaccine Safety in Children Aged 5–11 Years — United States, November 3–December 19, 2021
por: Hause, Anne M., et al.
Publicado: (2021)

Urban and Rural Mpox Incidence Among Persons Aged 15–64 Years — United States, May 10–December 31, 2022
por: Zelaya, Carla E., et al.
Publicado: (2023)

Safety Monitoring of COVID-19 mRNA Vaccine Second Booster Doses Among Adults Aged ≥50 Years — United States, March 29, 2022–July 10, 2022
por: Hause, Anne M., et al.
Publicado: (2022)

January 2022-December 2022
Publicado: (2022)

Letters of intent and proposals received up to November 9, 1973
por: Brandt, R, et al.
Publicado: (1973)

Awareness, Beliefs, and Actions Concerning Zika Virus Among Pregnant Women and Community Members — U.S. Virgin Islands, November–December 2016
por: Prue, Christine E., et al.
Publicado: (2017)

Investigation of a SARS-CoV-2 B.1.1.529 (Omicron) Variant Cluster — Nebraska, November–December 2021
por: Jansen, Lauren, et al.
Publicado: (2021)

Epidemiologic and Clinical Features of Mpox in Transgender and Gender-Diverse Adults — United States, May–November 2022
por: Blackburn, Dawn, et al.
Publicado: (2022)

Ventilation Improvements Among K–12 Public School Districts — United States, August–December 2022
por: Mark-Carew, Miguella, et al.
Publicado: (2023)

Geographic Distribution of Suspected Alpha-gal Syndrome Cases — United States, January 2017–December 2022
por: Thompson, Julie M., et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_jd4tac0bb7j0all24pf0bmptb0